The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland:The Prolactin Epidemiology, Audit, and Research Study (PROLEARS) by Soto-Pedre, Enrique et al.
                                                              
University of Dundee
The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of
Scotland
Soto-Pedre, Enrique; Newey, Paul J.; Bevan, John S.; Greig, Neil; Leese, Graham P.
Published in:
Clinical Endocrinology
DOI:
10.1111/cen.13156
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Soto-Pedre, E., Newey, P. J., Bevan, J. S., Greig, N., & Leese, G. P. (2017). The epidemiology of
hyperprolactinaemia over 20 years in the Tayside region of Scotland: The Prolactin Epidemiology, Audit, and
Research Study (PROLEARS). Clinical Endocrinology, 86(1), 60-67. DOI: 10.1111/cen.13156
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, 
which may lead to differences between this version and the Version of Record. Please 
cite this article as doi: 10.1111/cen.13156 
This article is protected by copyright. All rights reserved. 
Received Date : 11-May-2016 
Revised Date   : 22-Jun-2016 
Accepted Date : 14-Jul-2016 
Article type      : 1 Original Article - UK, Europe 
TITLE PAGE 
Title: The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of 
Scotland: The Prolactin Epidemiology, Audit, and Research Study (PROLEARS) 
Short title: Epidemiology of hyperprolactinaemia. 
Authors: Enrique Soto-Pedre 1, Paul J. Newey 1, 2, John S. Bevan 3, Neil Greig 4, Graham P. 
Leese 2 
Authors’ affiliations:  
1 Division of Molecular & Clinical Medicine, School of Medicine, Ninewells Hospital and 
Medical School, University of Dundee (Dundee, UK) 
2 Department of Endocrinology and Diabetes, Ninewells Hospital and Medical School, 
University of Dundee (Dundee, UK) 
3 JJR Macleod Centre for Diabetes, Endocrinology & Metabolism (Mac-DEM), Aberdeen Royal 
Infirmary, University of Aberdeen (Aberdeen, UK) 
4 Department of Clinical Biochemistry, Ninewells Hospital and Medical School, University of 
Dundee (Dundee, UK) 
Key words: hyperprolactinaemia, serum prolactin, cohort studies, prevalence, incidence. 
This is the peer reviewed version of the following article: 'The epidemiology of hyperprolactinaemia over 
20 years in the Tayside region of Scotland', Soto-Pedre, Leese, et al., which has been published in final 
form at http://dx.doi.org/10.1111/en.13156. This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Self-Archiving.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Corresponding author and person to who reprint requests should be addressed: 
Enrique Soto-Pedre MBBS, MSc 
Division of Molecular & Clinical Medicine, School of Medicine 
Level 5, Mailbox 12 
Ninewells Hospital and Medical School, University of Dundee 
Dundee DD1 9SY, Scotland (UK) 
Phone: +44(0)1382383585 Fax: +44(0)1382383598 E-mail: e.soto@dundee.ac.uk 
Acknowledgements: We wish to acknowledge the help of the FARR institute and the Health 
Informatics Centre, University of Dundee (Scotland, UK), and Dr. Louise Donnelly who 
provided support for data analysis. The study was funded in part by the Clinical 
Endocrinology Trust (UK Registered Charity Number 288679). There are no conflicts of 
interest. 
 
ABSTRACT 
Objective: To estimate the prevalence and incidence of hyperprolactinaemia. 
Hyperprolactinaemia is a common problem in endocrine practice, but its epidemiology has 
not been accurately established. 
Study design: A population-based retrospective follow up study in Tayside, Scotland 
(population 400,000) from 1993 to 2013.  
Patients: Record-linkage technology (biochemistry, prescribing, hospital admissions, 
radiology, mortality and maternity data) was used to identify all patients with a serum 
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prolactin measurement. From these, cases were defined as those with a prolactin greater 
than 1000mU/L (47.2ng/ml) or at least three prescriptions for a dopamine agonist. 
Measurements: Number of prevalent and incident cases of hyperprolactinaemia per 
calendar year by age, sex and cause of hyperprolactinaemia. 
Results: A total of 32,289 patients had a serum prolactin assay undertaken, of which 1,301 
had hyperprolactinaemia not related to pregnancy: 25.6% patients were pituitary-disorder 
45.9% drug-induced, 7.5% related to macroprolactin, and 6.1% related to hypothyroidism, 
leaving 15.0% idiopathic.  Over the 20 years there was a fourfold increase in the number of 
prolactin assays performed and prevalence of hyperprolactinaemia was initially 0.02%, but 
rose to 0.23% by 2013.  Overall incidence was 13.8 cases per 100,000 person-years (20.6 in 
2008-13) and was 3.5 times higher in women than in men. The highest rates were found in 
women aged 25-44 years.  Drug-induced causes tripled during the 20 years. 
Conclusions: Rising prevalence of hyperprolactinaemia is probably due to increased 
ascertainment and increased incidence of psychoactive drug-related causes. Rates are higher 
in women than in men but only before the age of 65 years. 
 
INTRODUCTION 
Prolactin is a pleiotropic hormone with defined effects on lactation and gonadal function, 
whilst also influencing numerous additional physiological processes encompassing 
metabolism, angiogenesis, neuronal function, osmoregulation and immunity 1, 2. 
Hyperprolactinaemia, an excess of serum prolactin above a laboratory reference limit, is a 
common problem in endocrine practice 3, 4.  
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Hyperprolactinaemia can be physiological, pathological or iatrogenic. The causes of 
persistent non-physiological hyperprolactinaemia (i.e. occurring outside of gestation or 
lactation) include drugs, hypothyroidism, and hypothalamic/pituitary disorders 5. The 
association with certain drugs is well documented, most commonly antipsychotic agents 6, 7. 
Other medications include antidepressants, anti-emetics and antihypertensive agents 8. 
Macroprolactin resulting from the formation of prolactin-immunoglobulin complexes is 
associated with apparent hyperprolactinemia, although not typically associated with clinical 
features due to limited bioavailability and bioactivity. Aside from these, idiopathic 
hyperprolactinaemia is not uncommon 3. Data from case series and cross-sectional studies in 
patients with hyperprolactinaemia suggest that prolactinomas and other pituitary tumour 
types (35-70%) and idiopathic hyperprolactinaemia (28-46%) are the most common 
categories 9-14, but the majority of studies excluded drug-induced cases. The large number of 
commonly prescribed medications associated with hyperprolactinaemia suggests it is likely 
to occur frequently in the population, although its frequency has rarely been documented; 
Vilar et al reported a prevalence of 14.5% drug induced cases from a sample of patients 
identified at ten endocrine centres in Brazil 11. Regardless of aetiology, hyperprolactinaemia 
may result in hypogonadism, infertility, amenorrhoea, galactorrhoea, and impotence or it 
may produce no symptoms 15. 
 
Hyperprolactinaemia may occur in men and women at any age, and its prevalence and 
incidence depends on the study population. Its epidemiology in the general population has 
not been accurately established, because available estimates are scarce and/or inadequate. 
Prevalence from cross-sectional studies seems to vary from 1.2-4.1% in healthy adults 16, 17 to 
3.9-30% in series of patients identified in various clinical settings; it was estimated at 3.9% in 
patients identified through a private large medical centre database, 7.9% among women 
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with menstruation related problems, 15.7% among women attending to an infertility clinic, 
18% in patients with systemic lupus erythematosus, and 30% among women receiving oral 
contraceptives 18-22. The prevalence was 3.1% among male patients with idiopathic sexual 
dysfunction 23. However results from a population-based cohort study showed a much lower 
overall prevalence of “ever” medically treated hyperprolactinemia that ranged from 0.02% 
in men to 0.09% in women, and incidence ranged from 1.4/100,000 person-years in men to 
8.7/100,000 person-years in women 24.   The prevalence of pituitary tumours have been 
shown to be around 1 per 1000 of the population 25, 26, with 44% being due to prolactinomas 
in one study 26.  However, population-based estimates of the incidence and prevalence of all 
causes of hyperprolactinaemia are still lacking. 
 
The Centre for Endocrine Epidemiology in Tayside (Scotland, UK) has undertaken data 
linkage to report on incidence and prevalence of thyroid dysfunction and primary 
hyperparathyroidism 27, 28. We aimed to use the same data linkage to estimate prevalence 
and incidence of all cause hyperprolactinaemia in the general population as well as the 
relative contribution of the respective causes. 
 
SUBJECTS AND METHODS 
Anonymised data from medical records of patients for the complete population of Tayside, a 
well-defined geographical region within Scotland (UK) with a population of 400,000 people, 
were reviewed between 1988 and 2014 (the most recent data available). Every patient in 
Tayside has a unique National Health Service (NHS) patient identifier (Community Health 
Index- CHI) number that has been used for all health related contacts, whether in primary, 
secondary or private health care. This allowed the electronic linkage of all databases used.  
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The Biochemistry database was linked to other databases by the Health Informatics Centre 
Services/ Farr Institute of Scotland at the University of Dundee 
(http://www.dundee.ac.uk/hic). These included demographic records (gender, birth and 
migration), Scottish Morbidity Records-SMR (maternity admissions, hospital admissions, and 
surgical procedures), Scottish Care Information-Diabetes Collaboration-SCI-DC database 
(data from primary care and diabetes clinics on diabetes mellitus), prescriptions dispensed, 
and the General Registrar Office-GRO records on patient deaths. Magnetic Resonance 
Imaging (MRI) reports were also accessed and linked for identifying pituitary tumours 29. 
 
Prolactin analyses were performed using three analytical platforms during the period of the 
study. Up to 2003 levels were measured by a Bayer® chemiluminescence immunoassay 
(Bayer PLC, Newbury, UK), from 2003 to 2012 by a Roche® E170 electrochemiluminescence 
analyser (Roche Diagnostics Limited, West Sussex, UK), and since then by a Siemens ADVIA 
Centaur XP® chemiluminescence analyser (Siemens Healthcare Diagnostics, Surrey, UK). The 
reference range for prolactin was less than 600mU/L (28.3ng/ml) for women and less than 
350mU/L (16.5ng/ml) for men, and did not change over time. All analyses had been 
performed at the Blood Sciences Department at the Ninewells Hospital (Dundee, UK).  
 
The International Classification of Diseases (ICD) 10th revision codes were used to identify 
hospital inpatient events, and the Office of Population Censuses and Surveys Classification of 
Surgical Operations version 4 codes (OPCS-4) to identify operations, procedures and 
interventions during inpatient stays. Prescriptions were identified by means of the British 
National Formulary (BNF) codes. 
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To ensure data quality, SMR data go through a set of validation rules by the Information 
Services Division (ISD-NHS National Services Scotland). These validation rules check on the 
validity and feasibility of the data 30. Besides, ISD carry out periodical data quality assurance 
exercises to evaluate and ensure SMR datasets are accurate, consistent and comparable 
across time and between sources 31. The study was approved by the Tayside Committee for 
Medical Research Ethics and conducted in accordance with the Declaration of Helsinki. 
 
Inclusion-exclusion criteria and case definition 
Patients with at least one serum prolactin measurement taken were considered for inclusion 
in the study. All patients who were pregnant or possibly lactating at the time of assay (i.e. 
within 9 months before and 12 months after delivery date) were excluded, unless they had 
raised prolactin measurements out with this time window. Any patient with at least one 
serum prolactin measurement greater than 1,000mU/L (47.2ng/ml) or three or more 
prescriptions of specific dopamine agonists (BNF 6.7.1: cabergoline, bromocriptine, and/or 
quinagolide) was considered a case, with subsequent allocation into one of five groups: 
1. Pituitary-disorder. Patients were selected if they had at least one serum prolactin 
measurement greater than 5,000mU/L (235.8ng/ml), or three or more prescriptions 
of specific dopamine agonists and/or a hospital admissions related to pituitary 
disorder (ICD10:  C751, E22, E23) and/or pituitary surgery (OPCS-4: B01, B02, B04) or 
a mass on pituitary MRI. 
2. Drug-induced. Patients were selected if they had a record of being prescribed 
drug(s) known to elevate prolactin levels within 6 months before and 1 month after 
the assessment of serum prolactin measurement, and did not fit into group 1. Any 
prescription of antipsychotics (BNF: 4.2.1, 4.2.2), tricyclics and related 
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antidepressants (BNF: 4.3.1), serotonin re-uptake inhibitors (BNF: 4.3.3), dopamine 
antagonists (BNF: 4.6), opioids and drugs used in opioid dependence (BNF: 4.7.2, 
4.10.3), H2 antagonists (BNF: 1.3.1), methyldopa (in BNF: 2.5.2), and verapamil (in 
BNF: 2.6.2) were extracted from the database containing prescriptions dispensed 
from all community pharmacies in Tayside. 
3. Macroprolactin. Patients were selected if they had presence of macroprolactin 
identified without any other explanation. 
4. Hypothyroidism. Patients were selected if they had a thyroid stimulating hormone 
(TSH) serum level > 6mU/L (0.28ng/ml) at some time without any other explanation. 
5. Idiopathic. Patients were selected if remained unclassified.  
 
Statistical analysis 
The period of study for the analysis of prevalence and incidence was defined between 
January 1st 1993 and January 1st 2013 to avoid bias introduced by incomplete ascertainment 
of cases before and after these dates. Any patient with at least one serum prolactin 
measurement greater than 1,000mU/L (47.2ng/ml) or three or more prescriptions of specific 
dopamine agonists at any time within a year was considered a prevalent case. Period 
prevalence was then estimated as the number of prevalent cases divided by the estimated 
mid-year population originated from the GRO records for Scotland, and it was calculated for 
every calendar year and for the entire period of study. For each patient the date of entry 
into the study was the date at first event of diagnosis identified within this period, and it was 
assumed that a patient after diagnosis stayed prevalent for the rest of the study until death 
or moving out of the health area. The incidence rate was calculated as the number of new 
(i.e. incident) cases divided by the number of person-years in the source population. Person-
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years were calculated for every calendar year separately and further combined for all 
calendar years to serve as the denominator of an overall incidence rate. Incidence rate was 
stratified by gender and 10-year age groups group (<15, 15-24, 25-34, 35-44, 45-54, 55-64, 
65-74, 75+); 95% confidence intervals (CIs) for these were calculated assuming a Poisson 
distribution. Standardized rates were calculated by applying the age/sex-stratified rates to 
the all-Scotland population from the 2001 and 2011 (estimates for 2002 to 2013) Census 
results. Data were entered into a STATA/SE® version 13.1 software package (StataCorp, USA) 
for statistical analysis and determination of statistical significance (P values <0.05). Logic 
checks were performed and frequency distributions for all variables were analysed for out-
of-range values. The mean and standard deviation or the median and the interquartile range 
of the data were calculated to describe continuous variables. ANOVA and chi-square tests 
were used to compare means and frequencies among subgroups of patients respectively. 
Nonparametric methods were used where appropriate32. 
 
RESULTS 
A total of 32,289 patients were identified with at least one measurement of a serum 
prolactin level in Tayside between 1988 and 2014, 1,366 of whom met the criteria for 
hyperprolactinaemia. After excluding 65 cases of hyperprolactinaemia associated with 
pregnancy, a total 1,301 cases were considered for the study. Demographic characteristics of 
the final study cohort are shown in Table 1. The mean age was 39.2 years, and 78.3% were 
women. Of these cases, the majority were drug-induced (45.9%), followed by pituitary-
disorder (25.4%). Drug-induced cases were older (mean age 42 years) and pituitary-disorder 
cases had the highest average of maximum serum prolactin concentration (2,426mU/l; 
114.4ng/ml) at diagnosis compared to other causes (P<0.001). Anti-psychotic and anti-
depressant medications accounted for 63.5% and 12.7% of drug-induced cases respectively, 
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and a total of 228 out of 598 drug-induced cases (38%) also had traces of macroprolactin. Of 
331 patients categorised as having a pituitary disorder we identified MRI pituitary scans in 
250 (76%). The remainder are likely to have had a scan outwith Tayside or at a time before 
the study entry. Out of pituitary caused cases found, 145 had confirmatory abnormalities on 
pituitary MRI, of which 91 (62.8%) were micro-adenomas, and 54 (37.2%) macro-adenomas.  
The respective data for micro-adenomas and macro-adenomas were: mean ages 35.9 and 
48.5 years (P<0.0001), percentage female 83.5% and 55.6% (P<0.0001), median maximum 
serum prolactin concentration of 2,103mU/L (99.2ng/ml) and 3,618mU/L (170.7ng/ml) 
(P=0.039).  In all other patients 111 underwent a pituitary MRI scan, all of which were 
normal. Overall 6.1% of cases patients had a TSH greater than 6mU/L (0.28ng/ml) and no 
other explanation for hyperprolactinaemia.  No cause could be found for the 
hyperprolactinaemia in 196 cases (15%), although 17 of these had undergone MRI scanning 
with a normal result, and these cases may have represented a micro-prolactinoma. 
 
Prevalence and incidence rates of ever treated and untreated (i.e. measured) 
hyperprolactinaemia were estimated for the period 1993-2013 for the population of Tayside 
that increased from 395,480 to 411,750 (table 2). There was also a steep increase in the 
number of serum prolactin assays carried out in Tayside around 2003, changing from 9,167 
in 1998-2002 to 34,221 in 2003-2007 (Table 3). The overall prevalence of ever having had 
hyperprolactinaemia was 107.3 cases per 100,000 population, and it was five times higher in 
women (175.2 per 100,000) than in men (35.1 per 100,000). Prevalence increased 
continuously over the calendar years from 0.02% in 1993 to 0.23% in 2013 (table 2). The 
average year-on-year increase was 15.7% for women and 17.2% for men.  
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A total number of 1,102 incident cases were ascertained (862 women and 240 men). Crude 
incidence rates were about three times higher in women than in men, and were lower in 
periods earlier than 2003 (table 3). When crude incidence rates were adjusted for age and 
sex using GRO for Scotland Census results, the overall rate was 13.8 per 100,000 person-
years (95%CI: 13.1- 14.7), with a rate of 21.5 per 100,000 person-years (95%CI: 20.0- 22.9) 
observed for women and 6.4 per 100,000 person-years (95%CI: 5.6- 7.2) for men. 
 
Incidence rate of hyperprolactinaemia increased for men through the study period, and 
increased for women from 2003. The increased rate over the last year periods (2003 to 
2013) was mostly due to an increase of drug-induced cases (table 4), but also due to an 
increased recognition of macroprolactin. There was also an increase of pituitary diagnoses 
for men in 2008- 2013 (table 4). 
 
When rates were examined for combined periods by age and sex groups (figure 1), the 
highest incidence rates of hyperprolactinaemia were found in women aged 25-44 years (25-
34 years: 49.6 per 100,000 person-years, 35-44 years: 42.7 per 100,000 person-years), and 
after this peak the incidence rates declined with age. In men, no peak was found, and the 
incidence rates ranged from 6 to 8.8 per 100,000 person-years in those people older than 15 
years. When rates were examined also by cause of hyperprolactinaemia (figure 2), a similar 
trend was observed in women for pituitary disorder, drug-induced, macroprolactin, and 
hypothyroid-related cases. In men, drug-induced and hypothyroid-related rates followed the 
same trend, but rates of pituitary disorder hyperprolactinaemia increased in those 
diagnosed over the age of 55 years and were also higher than in women. Incidence rates of 
idiopathic hyperprolactinaemia showed a peak in men and women aged 25-34 years. 
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DISCUSSION 
Over the last 20 years the prevalence of people having ever had hyperprolactinaemia 
increased from 22 to 232 per 100,000 in the 20 years following 1993, and steady state has 
not been achieved.  The prevalence was approximately five times greater in women than in 
men.  The adjusted incidence of all causes for hyperprolactinaemia was 13.8 per 100,000, 
increasing from 9 to 20 per 100,000 over 20 years.  The incidence in women was 3.5 times 
that observed in men, but there was little gender difference above the age of 55 years.  
There are a number of possible reasons for this increasing incidence and prevalence of 
hyperprolactinaemia. The number of prolactin tests performed across Tayside during the 
study period increased from 2,332 in 1993 to 8,688 per annum in 2012, with a steep increase 
in 2003 (5,306 prolactin tests). Increased number of tests would be expected to result in an 
increased ascertainment of cases of hyperprolactinaemia. There was an increased rate of 
drug-induced hyper-prolactinaemia, which is likely to reflect an increased use of anti-
psychotic and anti-depressant medications over this time.  Prolactin measurements are 
sometimes used as a marker of concordance in such patients.  Routine testing for 
macroprolactin started around 2002 and such diagnoses increased steadily after 2003, as the 
prevalence of idiopathic causes declined.  It is likely that many cases of idiopathic 
hyperprolactinaemia before 2002 were due to macroprolactin.   The increase in pituitary-
disorder diagnoses for men during the last period of study (2008- 2013) is intriguing and may 
reflect an increasing awareness of impotence and an increasing willingness to investigate it 
33.  It is difficult to be certain if there was real increase in hyperprolactinaemia or whether 
changes simply reflect an increased ascertainment, along with some real increase in drug-
induced cases.  Either way, the increased incidence does indicate an increased demand on 
health-care resources.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
As described previously, the prevalence of hyperprolactinaemia is reported to vary greatly 
from studies of healthy adults to series of patients identified in various clinical settings. 
Despite these variations, studies on community-based data reported prevalence of 
measured hyperprolactinaemia (women>600mU/L and men>400mU/L) between 1.2-1.4% 16 
from a relatively small cohort of 1,675 people, but in a study where all patients were 
sampled.  In another larger study the prevalence of hyperprolactinaemia, identified by use of 
more than one dopamine agonist prescription, was 0.03-0.17% 24.  The prevalence increased 
over the study period, due partly to an increasing incidence. Our results agree in part with 
those from the population-based cohort study of Kars et al. that showed a prevalence of 
ever medically treated hyperprolactinemia around 0.2% in recent years, and five times 
greater in women than in men 24. However, Kars at al. did not present data either on death 
or migration of patients, excluded individuals aged less than 15 years, and did not include 
untreated hyperprolactinaemia in their case ascertainment. 
 
Kars et al. reported an incidence rate of treated hyperprolactinaemia of 5.1 per 100,000 24.  
This mainly reflected pituitary tumours but possibly with some other cases of 
hyperprolactinaemia treated with dopamine agonists.  Unlike the Kars study our report 
included pituitary imaging (MRI) information, and reported an incidence of pituitary tumours 
of around 4 per 100,000 since the year 2000.  If several of our idiopathic group were due to 
micro-prolactinomas, then our figure would be very similar to that of Kars.  The highest 
incidence rate was found in women aged 25-34 years, and after this peak rates remained 
high in those aged 35-44 years, and declined with age similar to the Kars study 24. In men 
pituitary-disorder rates increased in those over the age of 55 years. This may reflect 
increasing investigation of impotence and low serum testosterone. The majority of pituitary 
caused cases (92.5%) were treated with dopamine agonists (three or more prescriptions), 
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but some milder cases remained untreated.  In addition to the Kars study we report a drug 
induced rate of hyperprolactinaemia of 6.7 per 100,000 indicating that this is now the 
commonest cause of hyperprolactinaemia.   
 
Defined cases in our study included patients with a serum prolactin greater than 1000mU/L 
(47.2ng/ml) and may thus have missed some cases of clinically-relevant hyperprolactinaemia 
with more modest prolactin elevations. This threshold of serum prolactin (rather than one 
defined according to gender specific reference ranges) was chosen because it represents a 
clinical relevant elevation of prolactin that deserves further investigation in practice, and 
thus additional health-care resources.  This particularly diagnostic criterion may have 
contributed to underestimate untreated hyperprolactinaemia mainly in men, but it seems 
unlikely to be  a major factor because our gender specific prevalence ratio was similar to 
that reported by Kars et al (fivefold higher for women than men)24.  The subcategorisation of 
cases depends on the algorithms employed, which may also introduce some error when 
identifying cause.  For example some patients with mild hyperprolactinaemia who did not 
have an MRI may have had abnormalities such as small tumours or stalk effect that were 
missed.  Such patients may have been miscategorised, but such patients were not treated 
with dopamine agonists or pituitary surgery, and it is unlikely that this was of clinical 
significance. Besides, we may have overestimated drug-induced hyperprolactinaemia, 
because if there was no other obvious cause for a raised serum prolactin (e.g. tumour or 
pregnancy), and a patient was on a drug that could cause hyperprolactinaemia, it was 
assumed to be the cause.  Unfortunately we do not have data on whether serum prolactin 
concentrations decreased when/if the causative drug was withdrawn.  The main impact of 
this would be an under diagnosis of “idiopathic” causes.  It is difficult to know what caused 
hyperprolactinaemia in the idiopathic group but could have included “over the counter” 
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medications e.g. anti-emetics, or early pregnancy which subsequently ended in miscarriage 
and longstanding untreated pituitary micro-adenomas that were not identified on other 
datasets.  Another possibility is that idiopathic hyperprolactinaemia was due to polycystic 
ovary syndrome, and indeed the peak incidence of idiopathic hyperprolactinaemia was in 
young women.  Unfortunately our data linkage and algorithms do not allow us to identify 
this phenotype. Hypothyroidism as a cause of hyperprolactinaemia may be an overestimate 
as our threshold of serum TSH at 6mU/L (0.28ng/ml) is quite low, although other studies 
have shown a similar or higher prevalence of hyperprolactinaemia in series of patients with 
overt or subclinical hypothyroidism  (8- 36%) 34, 35. However, our study is genuinely 
population-based and will have identified all cases of raised prolactin concentrations that 
were measured in Tayside.  
 
CONCLUSION 
In summary, this study demonstrates that overall prevalence of ever diagnosed 
hyperprolactinaemia in Tayside, Scotland, is 0.1%. Incidence rates are five times higher in 
women than in men, but are approximately the same over the age of 65 years. The observed 
increasing rate over time is possibly due to increased ascertainment and to an increased use 
of psychotropic drugs.  
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FIGURE LEGENDS 
FIGURE 1. Incidence rates of hyperprolactinaemia by age and sex groups. 
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FIGURE 2. Age-sex specific incidence rates of hyperprolactinaemia by cause of 
hyperprolactinaemia. 
TABLES 
 
TABLE 1 Description at first event of diagnosis of case patients not associated to pregnancy in Tayside from 1988 to 2014 by 
cause of hyperprolactinaemia. 
 
      Pituitary  Drug   
Characteristic  ALL   disorder  induced  Macroprolactin 
 Hypothyroidism Idiopathic   P * 
 
n (%)   1,301 (100.0)  331 (25.4)  598 (45.9)  97 (7.5) 
 79 (6.1)  196 (15.0)   -- 
 
Gender (female)  1,019 (78.3)  258 (78.0)  467 (78.1)  76 (78.4) 
 59 (74.7)  159 (81.1)   =0.815 
 
 
Mean (SD) 
 
Age (years)  39.2 (16.4)   39.3 (16.3)  41.9 (16.1)  35.1 (14.1) 
 33.0 (20.5)  35.2 (14.9)   <0.001 
    
Prolac?n (mU/L) †  1,636 (1,230-2,561)  2,426 (1,553- 5,310) 1,666 (1,266- 2,446) 1,321 (1,104- 
1,899) 1,406 (1,157- 1,794) 1,298 (1,113- 1,755)  <0.001 
 
SD= standard deviation (*) Difference among subgroups (†) Maximum serum concentration: median (interquartile range). The 
conversion factor from units to mass be 21.2; (mU/L)/21.2= ng/ml 
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TABLE 2. Prevalence of hyperprolactinaemia per calendar year by sex (1993- 2013) 
 
   WOMEN Prevalence  MEN   Prevalence
  TOTAL   Prevalence 
YEAR  Cases/population  per 100,000  Cases/population  per 
100,000  Cases/population  per 100,000 
1993    76/ 205,937    36.9     11/ 189,543    5.8
     87/ 395,480    21.9  
1994    93/ 205,913    45.1     14/ 190,067    7.3
   107/ 395,980    27.0  
1995  124/ 206,640    60.0     16/ 190,600    8.3
   140/ 397,240    35.2 
1996  154/ 206,023    74.7     21/ 189,877  11.0
   175/ 395,900    44.2 
1997  180/ 205,793    87.4     26/ 189,537  13.7
   206/ 395,330    52.1 
1998  206/ 205,053  100.4     27/ 188,997  14.2
   233/ 394,050    59.1 
1999  231/ 204,327  113.0     30/ 188,403  15.9
   261/ 392,730    66.4 
2000  255/ 203,098  125.5     35/ 187,332  18.6
   290/ 390,430    74.2 
2001  280/ 202,152  138.5     39/ 186,628  20.8
   319/ 388,780    82.0 
2002  310/ 201,947  153.5     45/ 186,363  24.1
   355/ 388,310    91.4  
2003  345/ 202,257  170.5     52/ 186,483  27.8
   397/ 388,740  102.1  
2004  367/ 202,971  180.8     56/ 187,199  29.9
   423/ 390,170  108.4  
2005  404/ 204,332  197.7     65/ 188,668  34.4
   469/ 393,000  119.3  
2006  445/ 205,421  216.6     71/ 189,839  37.4
   516/ 395,260  130.5  
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2007  493/ 206,843  238.3     94/ 191,537  49.0
   587/ 398,380  147.3  
2008  553/ 208,410  265.3   110/ 193,500  56.8
   663/ 401,910  164.9  
2009  600/ 209,437  286.4   130/ 194,933  66.6
   730/ 404,370  180.5  
2010  650/ 210,510  308.7   148/ 196,560  75.2
   798/ 407,070  196.0  
2011  700/ 211,607  330.8   172/ 198,643  86.5
   872/ 410,250  212.5  
2012  767/ 212,161  361.5   188/ 199,589  94.1
   955/ 411,750  231.9  
 
Overall  --   175.2   --   35.1
    --   107.3  
[95%CI]    [171.5- 179.6]     [33.5- 37.3]
     [105.8- 110.5]  
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TABLE 3. Incidence rate (per 100,000 person-years) of hyperprolactinaemia per year period by sex 
(1993- 2013) 
 
WOMEN   MEN   
   TOTAL 
   
PERIOD Tests †  Crude  Adjusted *  Crude   Adjusted *
   Crude  Adjusted * 
 
1993- 1997 10,187  15.9  16.0 [13.5- 18.4]    2.1    2.2 
[1.2- 3.2]     9.3    9.2 [7.9- 10.6] 
 
1998- 2002   9,167  16.8  17.0 [14.5- 19.6]    4.7    4.9 
[3.4- 6.3]   11.0  11.0 [9.5- 12.5] 
 
2003- 2007 34,221  22.1  22.9 [19.9- 25.9]    7.2    7.3 
[5.6- 9.1]   15.0  15.2 [13.5- 17.0] 
 
2008- 2013 42,487  28.6  29.8 [26.4- 33.2]  11.0  11.1 
[9.0- 13.2]   20.1  20.6 [18.6- 22.6] 
 
Overall  96,062  20.9  21.5 [20.0- 22.9]    6.3    6.4 
[5.6- 7.2]   13.8  13.8 [13.1- 14.7] 
 
(*) Age-sex standardized [95% Confidence interval]  
(†) Number of prolac?n tests performed in Tayside. 
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TABLE 4. Incidence rate (per 100,000 person-years) of hyperprolactinaemia per year period by sex and cause 
(1993- 2013) 
 
WOMEN     MEN  
   TOTAL 
PERIOD    Crude  Adjusted *  Crude  
 Adjusted *  Crude  Adjusted * 
 
PITUITARY DISORDER 
1993- 1997     4.7    4.7 [3.4- 6.1]  0.9  1.0 
[0.3- 1.7]    2.9    2.9 [2.1- 3.6] 
1998- 2002     5.8    5.8 [4.4- 7.3]  1.8  1.9 
[1.0- 2.8]    3.9    3.9 [3.0- 4.7] 
2003- 2007     6.9    7.1 [5.4- 8.7]  1.1  1.1 
[0.4- 1.7]    4.1    4.1 [3.2- 5.0] 
2008- 2013     4.6    4.7 [3.4- 6.1]  2.6  2.7 
[1.6- 3.7]    3.6    3.7 [2.9- 4.5] 
Overall     5.5    5.6 [4.9- 6.3]  1.6  1.7 
[1.3- 2.1]    3.6    3.6 [3.2- 4.1] 
DRUG INDUCED 
1993- 1997     5.7    5.7 [4.3- 7.2]  0.5  0.6 
[0.1- 1.1]    3.2    3.2 [2.4- 4.0] 
1998- 2002     5.7    5.8 [4.3- 7.3]  1.3  1.4 
[0.6- 2.1]    3.6    3.6 [2.7- 4.4] 
2003- 2007   11.1  11.3 [9.2- 13.4]  4.1  4.2 
[2.9- 5.5]    7.7    7.8 [6.6- 9.1] 
2008- 2013   16.7  17.3 [14.7- 19.9]  6.0  6.1 
[4.5- 7.6]  11.5  11.8 [10.3- 13.3] 
Overall     9.9  10.1 [9.1- 11.1]  3.0  3.1 
[2.5- 3.7]    6.6    6.7 [6.1- 7.2] 
MACROPROLACTIN 
1993- 1997     0.1  0.1 [0.0- 0.3]  0.1  0.1 
[0.0- 0.4]    0.1    0.1 [0.0- 0.3] 
1998- 2002     0.2  0.2 [0.0- 0.5]  0.0  -
       0.1    0.1 [0.0- 0.3] 
2003- 2007     0.8  0.8 [0.3- 1.4]  0.5  0.5 
[0.1- 1.0]    0.7    0.7 [0.3- 1.1] 
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2008- 2013     4.7  4.9 3.6- 6.3]  1.4  1.4 
[0.7- 2.2]    3.1    3.2 [2.4- 4.0] 
Overall     1.5  1.5 [1.1- 1.9]  0.5  0.5 
[0.3- 0.7]    1.0    1.0 [0.8- 1.2] 
HYPOTHYROIDISM 
1993- 1997     2.0  2.1 [1.2- 2.9]  0.5  0.5 
[0.1- 0.9]    1.3    1.3 [0.8- 1.8] 
1998- 2002     0.7  0.7 [0.2- 1.3]  0.3  0.4 
[0.0- 0.8]    0.5    0.5 [0.2- 0.9] 
2003- 2007     0.8  0.8 [0.2- 1.3]  0.5  0.5 
[0.1- 1.0]    0.7    0.6 [0.3- 1.0] 
2008- 2013     0.8  0.8 [0.2- 1.3]  0.3  0.3 
[0.0- 0.6]    0.5    0.5 [0.2- 0.9] 
Overall     1.1  1.1 0.8- 1.4]  0.4  0.4 
[0.2- 0.6]    0.8    0.8 [0.6- 1.0] 
IDIOPATHIC 
1993- 1997     3.4  3.3 [2.2- 4.5]  0.0  -
     1.8    1.7 [1.1- 2.3] 
1998- 2002     4.4  4.5 [3.2- 5.8]  1.3  1.3 
[0.6- 2.0]    2.9    2.9 [2.2- 3.7] 
2003- 2007     2.6  2.9 [1.8- 3.9]  1.0  1.0 
[0.3- 1.6]    1.8    1.9 [1.3- 2.5] 
2008- 2013     1.9  2.0 [1.1- 2.9]  0.6  0.6 
[0.1- 1.2]    1.3    1.3 [0.8- 1.9] 
Overall     3.1  3.2 [2.6- 3.7]  0.7  0.7 
[0.4- 1.0]    1.9    2.0 [1.7- 2.3] 
 
(*) Age-sex standardized [95% Confidence interval] 
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